What does the evidence say about Spirulina Cardiometabolic Markers Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Spirulina Cardiometabolic Markers Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Results: Spirulina supplementation reduced infarct size by 64%, increased myocardial salvage by 18%, and improved cardiac function by 30% vs. [Vilahur G (2022); evidence level 4] - controls ( p p Conclusion: A 10-day supplementation with spirulina exerts cardioprotection in a preclinical setting of STEMI by limiting cardiac damage and improving ventricular contractility through anti-oxidative, anti-inflammatory, and anti-apoptotic mechanisms. [Vilahur G (2022); evidence level 4] - Background and Aims: Myocardial infarction (MI) is the clinical manifestation of atherosclerotic coronary artery disease. [Vilahur G (2022); evidence level 4] - Spirulina is an algae known to ameliorate cardiometabolic disorders and with proven anti-inflammatory and anti-oxidant effects. [Vilahur G (2022); evidence level 4] - It is associated with underlying low-grade inflammation, thus is a risk factor for the development of cardiometabolic alterations. [Gómez-Téllez A (2020); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.